Raynaud's phenomenon (RP) is a functional vascular disorder involving extremities. In his practice, the dermatologist may frequently encounter RP which affects mainly women and is categorized into a primary benign form and a secondary form associated with different diseases (infections, drugs, autoimmune and vascular conditions, hematologic, rheumatologic and endocrinologic disorders). Still today, the differential diagnosis is a clinical challenge. Therefore, a careful history and a physical examination, together with laboratory tests and nailfold capillaroscopy are mandatory. RP is generally benign but a scheduled follow-up for primary RP patients should be established, due to risk of evolution to secondary RP. A combination of conservative measures and medications can help in the management of RP. The importance of avoiding all potential physical, chemical and emotional triggers, as well as quitting smoking should be strongly suggested to the patient. As first line treatment, dihydropyridine Calcium Channel Blockers should be used. If this approach is not sufficient, prostacyclin derivatives, phosphodiesterases inhibitors and endothelin receptor antagonists can be considered as second line treatment. In cases of acute ischemia nifedipine and intravenous prostanoidsare helpful. In refractory cases, botulinum injections have shown a significant benefit. The approach to the RP patients requires therefore a coordinated care of specialists together with the primary care physician. This article is protected by copyright. All rights reserved.

The role of the dermatologist in Raynaud's Phenomenon: a clinical challenge / Matucci-Cerinic, Caterina; Nagaraja, Vivek; Prignano, Francesca; Kahaleh, Bashar; Bellando-Randone, Silvia. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - ELETTRONICO. - (2018), pp. 1-2. [10.1111/jdv.14914]

The role of the dermatologist in Raynaud's Phenomenon: a clinical challenge

MATUCCI CERINIC, CATERINA
;
Prignano, Francesca
;
Bellando-Randone, Silvia
2018

Abstract

Raynaud's phenomenon (RP) is a functional vascular disorder involving extremities. In his practice, the dermatologist may frequently encounter RP which affects mainly women and is categorized into a primary benign form and a secondary form associated with different diseases (infections, drugs, autoimmune and vascular conditions, hematologic, rheumatologic and endocrinologic disorders). Still today, the differential diagnosis is a clinical challenge. Therefore, a careful history and a physical examination, together with laboratory tests and nailfold capillaroscopy are mandatory. RP is generally benign but a scheduled follow-up for primary RP patients should be established, due to risk of evolution to secondary RP. A combination of conservative measures and medications can help in the management of RP. The importance of avoiding all potential physical, chemical and emotional triggers, as well as quitting smoking should be strongly suggested to the patient. As first line treatment, dihydropyridine Calcium Channel Blockers should be used. If this approach is not sufficient, prostacyclin derivatives, phosphodiesterases inhibitors and endothelin receptor antagonists can be considered as second line treatment. In cases of acute ischemia nifedipine and intravenous prostanoidsare helpful. In refractory cases, botulinum injections have shown a significant benefit. The approach to the RP patients requires therefore a coordinated care of specialists together with the primary care physician. This article is protected by copyright. All rights reserved.
2018
1
2
Matucci-Cerinic, Caterina; Nagaraja, Vivek; Prignano, Francesca; Kahaleh, Bashar; Bellando-Randone, Silvia
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1119220
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact